Hypothermia Protocols in Neonatal HIE: A Global Review

When an infant is deprived of adequate oxygen or blood flow around the time of birth, a cascade of injury unfolds across the newborn brain. This condition, hypoxic-ischemic encephalopathy, remains a leading cause of acquired neonatal mortality and long-term neurodevelopmental disability worldwide. Over the past two decades, therapeutic hypothermia has shifted from an experimental intervention to the cornerstone of neuroprotective care for affected term and near-term infants.

The principle is straightforward: by cooling the body to 33.0–34.5 °C within six hours of birth and maintaining that target for 72 hours, clinicians slow the secondary energy failure that would otherwise destroy neurons and white matter. Yet translating that biology into consistent bedside practice has required enormous coordination among neonatologists, nurses, retrieval teams, and parents — and the protocols used in Melbourne, Toronto, Stockholm, Tokyo, and Singapore differ in clinically meaningful ways.

The Pathophysiology Behind Cooling Therapy

After a sentinel hypoxic-ischemic event, the immature brain passes through distinct injury phases. The primary failure phase occurs during the insult itself, when high-energy phosphates are depleted and cellular membranes depolarise. If resuscitation restores circulation, a latent phase of 30 to 60 minutes follows, during which oxidative metabolism recovers transiently. Cooling must be initiated during this latent window to interrupt the secondary failure phase, a delayed cascade of excitotoxicity, inflammation, and programmed cell death that begins roughly six hours after the insult.

The protective effect of mild hypothermia is multifactorial. Cooling reduces cerebral metabolic rate, decreases excitatory neurotransmitter release, limits free-radical injury, and suppresses apoptotic pathways. Keeping core temperature just below the physiological norm achieves meaningful neuroprotection while avoiding bradycardia, coagulopathy, and electrolyte shifts. The 33.0–34.5 °C range has become the international consensus, though precise limits vary by guideline.

Australian Practice and Local Realities

In Australia, therapeutic hypothermia has been embedded in neonatal intensive care for nearly two decades, supported by the Australian and New Zealand Neonatal Network (ANZNN) registry and endorsed by the Neonatal Society of Australia and New Zealand. Major perinatal centres in Sydney, Melbourne, Brisbane, and Perth offer active cooling, and regional units can initiate passive cooling while arranging retrieval through services such as NETS. Public funding through Medicare and state-based perinatal networks means eligible infants receive cooling without out-of-pocket cost.

Distance remains a defining challenge. A baby born in remote Western Australia or Far North Queensland may need cooling in transit, often using servo-controlled mattresses during fixed-wing transfer to a tertiary centre. Indigenous Australian infants are disproportionately represented in remote-birth cohorts, and cultural safety is now formally integrated into perinatal guidelines, requiring plain-language communication and involvement of Aboriginal Liaison Officers where appropriate. The Royal Australian College of Physicians recommends structured neurodevelopmental surveillance to at least school age following cooling.

North American Guidelines and Their Reach

The American Academy of Pediatrics published a widely cited clinical report aligned with the original CoolCap and NICHD protocols: cooling initiated within six hours of birth, target 33.5 °C, and a 72-hour maintenance phase followed by slow rewarming at no more than 0.5 °C per hour. The report emphasises strict entry criteria, including evidence of perinatal depression and moderate encephalopathy on a structured neurological examination.

Canadian practice follows the Canadian Paediatric Society's position statement, which adds nuance for infants born at 35–36 weeks' gestation — a group historically excluded from cooling trials. Several Canadian centres now offer cooling for late-preterm infants with caution, and Quebec-based registries have helped characterise outcomes in this population. Across North America, protocols typically use either a whole-body cooling blanket or a head-only cap, with whole-body systems favoured for their more stable core temperature control and easier nursing access.

European Frameworks for Therapeutic Hypothermia

European centres contributed much of the foundational evidence base, beginning with the CoolCap trial in 2000 and the TOBY study in 2009. The European Consensus Guidelines recommend either whole-body cooling to 33.5 °C or selective head cooling to 34.5 °C for 72 hours. The choice between modalities is often dictated by equipment availability rather than outcome data, as meta-analyses have shown comparable efficacy when protocols are followed rigorously.

In the United Kingdom, the TOBY cooling register provided a template for population-based surveillance, and similar national registries now exist in Sweden, the Netherlands, and Germany. These datasets have clarified important safety signals, including the recognition that infants with severe coagulopathy or those born below 35 weeks require especially cautious selection. Continuous amplitude-integrated EEG monitoring is standard during cooling in most tertiary European NICUs, allowing clinicians to titrate sedation and counsel families about prognostic trajectories.

Practice Patterns Across Asia and Oceania

Practice across Asia is heterogeneous, reflecting differences in resource availability, transport infrastructure, and population density. Japanese centres, including several that would have participated in the FAOPS 2020 program, have adopted the 33.0–34.0 °C whole-body approach and have published outcome data suggesting benefit even in infants with severe encephalopathy. Singapore's KK Women's and Children's Hospital and tertiary units in South Korea run hybrid protocols that combine servo-controlled cooling with cerebral oximetry.

In low-resource settings across South and Southeast Asia, passive cooling — using gel packs or simply turning off radiant warmers — has become a pragmatic alternative when servo-controlled devices are unavailable. Indian neonatal networks have documented feasible cooling pathways even in district hospitals. Related perinatal challenges, such as the updates on the management of twin to twin transfusion syndrome, continue to demand coordinated multidisciplinary care across the region.

Side-by-Side: How Regional Protocols Differ

A practical question for clinicians training in one system and practising in another is how the major regional protocols actually compare. The differences are mostly subtle — centring on half-degree temperature targets, inclusion of late-preterm infants, and the choice between head and body cooling — but they matter when infants are transferred across borders or when multinational trials try to harmonise outcomes.

Across these settings, the rewarming phase is remarkably consistent — slow rewarming at no more than 0.5 °C per hour, with continuous monitoring for rebound seizures or hypotension.

Refinements, Nursing Care, and Family-Centred Practice

Even with optimal cooling, a substantial proportion of cooled infants still die or survive with significant disability. This has driven interest in adjunctive neuroprotective strategies. Erythropoietin, melatonin, xenon, and magnesium sulfate have all been investigated, though none has yet entered routine guideline-driven care. The HEAL and CoolXen trials examined xenon as add-on therapy but did not demonstrate the additive benefit hoped for, partly because xenon delivery requires specialised equipment that limits scalability.

Research is exploring whether deeper cooling (32.0 °C) might benefit infants with the most severe injury, balanced against risks of arrhythmia and thrombocytopenia. Non-invasive biomarkers — including heart rate variability, near-infrared spectroscopy, and serum tau levels — are being evaluated as early predictors of response.

Cooling is delivered hour by hour at the cot side, and nursing expertise is the single most important determinant of safe practice. Continuous temperature monitoring, careful titration of cooling blankets, meticulous fluid balance, and vigilant assessment for subcutaneous fat necrosis all sit within the nursing domain. Skin integrity in cooled infants is a particular concern, and structured neonatal skincare guidelines — including the practical advice compiled in neonatal skin care best practices for the very preterm infant — translate well to the cooled population.

Family presence during cooling has expanded significantly. Many Australian and New Zealand units now encourage parents to hold their baby's hand and participate in neurodevelopmental rounds. Discharge planning begins on day one, with referrals to early-intervention services and feeding specialists coordinated before the infant goes home.

Practical priorities for clinicians implementing or auditing a cooling program:

• Maintain core temperature within 33.0–34.5 °C for 72 hours; avoid overshoot below 32.0 °C.
• Use servo-controlled cooling devices wherever available; passive cooling is acceptable only as a bridge.
• Initiate amplitude-integrated EEG within the first 24 hours and repeat before rewarming.
• Plan retrieval logistics before birth when antenatal surveillance suggests possible HIE.

Family-facing priorities to communicate during the cooling window:

• Explain each step in plain language, using visual aids when possible.
• Encourage skin-to-skin contact during rewarming, when thermoregulation allows.
• Discuss the likely trajectory honestly, including the possibility of evolving prognosis.
• Connect families with peer-support groups and structured follow-up clinics.

If your team is planning a cooling protocol review or building retrieval pathways for regional referrals, the resources and conversation started at FAOPS 2020 remain a useful point of reference — explore the program archives and speaker materials to connect with colleagues across perinatal medicine.